HOME >> BIOLOGY >> NEWS
Introgens gene drug demonstrates tumor growth control

or that the proposed treatments will prove to be safe and/or effective. The actual results may differ from those described in this press release due to risks and uncertainties that exist in Introgens operations and business environment, including, but without limitation, Introgens stage of product development and the limited experience in the development of gene-based drugs in general, its dependence upon proprietary technology and current competition, history of operating losses and accumulated deficits, Introgens reliance on collaborative relationships, and uncertainties related to clinical trials, safety, efficacy, the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks detailed from time to time in Introgens filings with the Securities and Exchange Commission, including its prospectus dated October 12, 2000, filed with the Securities and Exchange Commission and the 10-K filed with the Securities and Exchange Commission on September 19, 2001. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising from the date hereof.


'"/>

Contact: Channing Burke
c.burke@introgen.com
512-708-9310
Porter Novelli
25-Oct-2001


Page: 1 2 3 4

Related biology news :

1. New genetic research demonstrates possible cause of inherited form of Parkinsons disease
2. Study demonstrates altered angiogenic proteins in preeclampsia patients
3. New study demonstrates bone protein can reverse kidney failure
4. Study demonstrates that low dose tamoxifen may be effective in treating breast cancer
5. Animal study demonstrates carbon monoxide may help heart patients
6. Binary enzyme created by TSRI scientists demonstrates Darwinian evolution at its simplest
7. New UGA study demonstrates bacterial pathogens use hydrogen as energy source in animals
8. Inhibitor of novel cancer target, LPAAT-beta, demonstrates selective anti-cancer effects
9. Norwegian study demonstrates targeted coxibs may prevent oral cancer
10. New physical activity opinion survey demonstrates perceptions do not meet reality
11. Testosterone gel (AndroGel) study demonstrates safety and efficacy up to 42 months

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Introgens gene drug demonstrates tumor growth control

(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... has dedicated his career to understanding the Earth,s ... audience. , As deputy director and regional climatologist ... Desert Research Institute, Redmond has more than three ... dissemination of climate data to the general public. ... San Francisco on December 15-19, 2014 the American ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
(Date:11/21/2014)... (PRWEB) November 20, 2014 ... (XNA, Chassis, Oligos, Enzymes, Cloning kits), Technology ... Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global ... major market drivers, threats, opportunities, and challenges. ... 46 figures spread through 185 pages and ...
(Date:11/21/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Sodium ferrocyanide ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/21/2014)... and SAN DIEGO , Nov. 20, 2014 ... President and CEO Marc Hedrick , M.D. will present ...   Thursday, December 4, 2014 TIME:    11:15 am ... or paste this URL into your browser,s address bar: ... pre-register to save time and receive event updates. ...
(Date:11/18/2014)... 17, 2014 Cirrascale Corporation ... blade-based and rackmount computing infrastructure, today announced it ... accelerator throughout its GPU-enabled blade server and high-performance ... company’s latest proprietary 80-lane Gen3 PCIe switch-enabled risers, ... Tesla K80 dual-GPU accelerator cards in a single ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
Cached News: